Shanghai Tanti Biomedical Technology

Shanghai Tanti Biomedical Technology is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a primary focus on molecular glue degraders (MGDs). Founded in 2021, the company leverages a proprietary platform to identify and optimize small molecules that induce the degradation of previously "undruggable" disease-causing proteins. Tanti Biomedical's research is primarily directed toward oncology and autoimmune indications, aiming to provide more effective treatment options for patients with high unmet medical needs. The company is headquartered in Shanghai and is backed by prominent venture capital investors, including 5Y Capital and Gaorong Capital.